Clinical Costs for Orphan Drugs Lower Than Non-Orphan Drugs, Study Finds

As almost 60% of new drug approvals in 2018 were for orphan drugs, a new review published in the Orpanet Journal of Rare Diseases finds that for new molecular entities, clinical costs for orphan drugs are half as much as such costs for non-orphan drugs.